Serum IgG Subclass May Be Indicator of Treatment Effect in Multiple Myeloma
May 18th 2022The researchers found that among subclasses, IgG1 expression was most prominent in samples from patients with multiple myeloma, and expression of IgG1 changed significantly before, throughout, and following treatment.
Read More
Dupilumab Clinically Effective Long Term for Moderate to Severe Pediatric Atopic Dermatitis
May 17th 2022Findings of the 52-week phase 3 LIBERTY AD PED-OLE trial showed dupilumab to have an adequate safety profile and incremental clinical benefit with continued use among pediatric patients with moderate to severe atopic dermatitis.
Read More
Trends Show Uptake of SUD Treatment Has Room for Improvement
May 17th 2022On this episode of Managed Care Cast, we speak with one of the authors of a paper published this month in Health Affairs about the utilization of substance use disorder treatment (SUD) services between 2010 and 2019, and why more needs to be done to get more individuals into treatment.
Listen
Contributor: The Convergence of Value-Based Care and Lab Testing Growth
May 17th 2022Today, health plans are shifting dollars to more value-based contracts along with investments in population health management. Digitizing lab results across all care settings and unlocking the potential of lab values can help health plans reach the Triple Aim of improving the patient experience, improving the health of populations, and reducing the per-member cost of health care.
Read More
The FDA announces it will streamline the review process to make it easier for foreign manufacturers to ship more formula to the US; researchers in Australia find babies with sudden infant death syndrome (SIDS) have low levels of butyrylcholinesterase in their blood; the federal government approves a third round of COVID-19 test kits and the FDA is expected to authorize booster shots for children aged 5 to 11 years.
Read More
Greater Biologic Persistence, Adherence Achieved With Ixekizumab for Psoriasis
May 16th 2022Significantly greater persistence, adherence, and time on monotherapy was achieved with the use of ixekizumab vs the biologics adalimumab, etanercept, secukinumab, and ustekinumab, in the treatment of moderate to severe psoriasis.
Read More
FDA to make an announcement regarding importation of baby formula; first-line use of nivolumab and ipilimumab vs standard of care chemotherapy fails to meet primary end point of overall survival in phase 3 CheckMate 901 trial; study finds link between antibiotic prescriptions and inflammatory bowel disease diagnosis in older adults.
Read More
Contributor: Congress Must Act to Stop America’s Amputation Epidemic
May 16th 2022The Amputation Reduction and Compassion Act (H.R. 2631) would ensure that Medicare and Medicaid both cover peripheral artery disease screening for at-risk beneficiaries without the cost-sharing requirements that could make some patients balk at seeking care.
Read More
The UK’s The Food Chain Fosters Food Engagement for PLWH Through Cooking
May 16th 2022Anna Brewster, services and volunteer manager at The Food Chain, a London-based charity that provides short-term assistance to persons living with HIV (PLWH), discusses how education provided through the Eating Positively program connects the importance of food and proper nutrition to health outcomes.
Watch
Superior Clinical Outcomes Seen in HFrEF With Early Initiation of Sacubitril/Valsartan
May 16th 2022Two periods of sacubitril/valsartan initiation were compared in a study population of patients with heart failure with reduced ejection fraction (HFrEF): less than 3 months or 3 or more months following first HFrEF diagnosis.
Read More
Superior T1D Control Seen With HCL Systems vs SAP Therapy in Older Adults
May 15th 2022Type 1 diabetes (T1D) can be especially difficult to manage in older adults, so this new multinational review compared the safety and effectiveness of a hybrid closed-loop (HCL) system and sensor-augmented pump (SAP) therapy.
Read More
Repurposing a Drug Used for Alcohol Abuse May Overcome MM Treatment Resistance
May 15th 2022According to recent findings, metabolizing disulfiram into diethyldithiocarbamate-copper complex creates a proteasome inhibitor-like treatment that enables the efficient killing of treatment-resistant multiple myeloma (MM) cells.
Read More